Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe

Connecticut Medicine

Volumn 69, Issue 1, 2005, Pages 19-22

  Perkerson, Kristen A ^a,b   Gillespie, Effie L ^a,c   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; CYTOCHROME P450 3A4; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LIPOPROTEIN; MEVINOLIN; NEFAZODONE; NELFINAVIR; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; REVIEW;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES;

EID: 12344330415     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. American Heart Association: Heart Disease and Stroke Statistics-2004 Update. Dallas, Texas: American Heart Association; 2003. Available at: http://www.americanheart.org/download-able/heart/ 1079736729696HDSStats2004UpdateREV3-19-04.pdf. Accessed July 2004.
2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
3. Castelli WP, Garrison RJ, Wilson PWF, et al: Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986; 256:2835-8.
4. Stamler J, Daviglus ML, Garside DB, et al: Relationship of baseline serum cholesterol levels in three large cohorts of younger men to long-term coronary, cardiovascular and all-cause mortality and to longevity. JAMA 2000; 284:311-8.
5. Wilson PWF, Christiansen JC, Anderson KM, et al: Impact of national guidelines for cholesterol risk factor screening: The Framingham offspring study. JAMA 1989; 262:41-4.
6. Schwartz GG, Olsson AG, Ezeckowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. MIRACL study. JAMA 2001; 285:1711-8.
7. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994; 344:1383-9.
8. Shepard J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-7.
9. Sacks FM, Pfeffer MA, Moye LA, et al: The effects of pravastatin on coronary events after myocardial infarction with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
10. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-22.
11. The Top 200 Prescriptions for 2003 by Number of US Prescriptions Dispensed. Available at: http://www.rxlist.com/top200.htm, Accessed: July 2004.
12. Mevacor [package insert]. West Point, PA: Merck & Co.; June 2002.
13. Pravachol [package insert]. Princeton, NJ: Bristol-Myers Squibb; December 2001.
14. Lescol, Lescol XL [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; October 2001.
15. Zocor [package insert]. West Point, PA: Merck & Co.; September 2003.
16. Lipitor [package insert]. New York, NY: Pfizer Inc.; August 2003.
17. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 93:152-60.
18. Davidson MH, McGarry T, Bettis R, et al: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40:2125-34i)
19. Goldberg AC, Spare A, Liu J, et al: Efficacy and safety of ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79:620-629.
20. Kerzner B, Corbelli J, Sharp S, et al: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91:418-24.
21. Melani L, Mills R, Hassman D, et al: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Eur Heart J 2003; 24:717-28.
22. Ballentyne CM, Houri J, Notarbartolo A, et al: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003; 107:2409-15.
23. Pearson TA, Laurora I, Chu H, Kafonek S: The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459-67.
24. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators: Comparative dose efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81:582-587.
25. White CM: HMG CoARI reductase inhibitor-induced muscle toxicity: risks, monitoring, and management. Formulary 2002; 37:588-93.
26. Zetia [package insert]. North Wales, PA: Merck/Schering-Plough Pharmaceuticals; March 2003.
27. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds): Cost-effectiveness in health and medicine. Oxford University Press, New York, NY, 1996.